Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,820 result(s) found. Displaying page 75 of 141.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    EudraCT Number: 2022-000557-88 Sponsor Protocol Number: Anti-CD19-ALL Start Date*: 2022-11-14
    Sponsor Name:University Hospital Tuebingen
    Full Title: A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage L...
    Medical condition: B-lineage (CD19 positive) ALL (B, pro-B, pre-B or c-ALL) refractory to standard treatment or with relapsed disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10024338 Leukemia lymphoblastic acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000885-39 Sponsor Protocol Number: 02289 Start Date*: 2021-01-12
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000444-26 Sponsor Protocol Number: 17-BI-1206-02 Start Date*: 2018-05-02
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractor...
    Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Ongoing) PL (Prematurely Ended) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002370-31 Sponsor Protocol Number: IMA203-101 Start Date*: 2020-03-10
    Sponsor Name:Immatics US InC
    Full Title: Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients wi...
    Medical condition: Recurrent and / or refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003699-60 Sponsor Protocol Number: KIBB01 Start Date*: 2018-09-28
    Sponsor Name:Karolinska Institutet
    Full Title: An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal intravenous administration of allogeneic expanded fetal...
    Medical condition: Treatment of Osteogenesis Imperfecta (OI) type III and severe type IV.
    Disease:
    Population Age: In utero, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003648-55 Sponsor Protocol Number: EZH-301 Start Date*: 2020-08-17
    Sponsor Name:Epizyme, Inc.
    Full Title: A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
    Medical condition: Phase 1b: Have histologically confirmed Soft tissue sarcoma (STS). Phase 3: Morphology and immunophenotypic panel consistent with epithelioid sarcoma (eg, CD34, epithelial membrane antigen [EMA], ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001335-31 Sponsor Protocol Number: virus-specific_CD8_T-cells_001 Start Date*: 2013-11-08
    Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta
    Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation
    Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003387-12 Sponsor Protocol Number: DopamineGenetics01 Start Date*: 2018-03-15
    Sponsor Name:University Hospital Tuebingen
    Full Title: Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study
    Medical condition: Adipositas ist eine weit verbreitete und in ihrer Prävalenz zunehmende Erkrankung, die mit schwerwiegenden Folgeerkrankungen einhergeht. Von häufigen genetischen Polymorphismen haben Varianten im F...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10051361 Adipositas LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    20.0 10027433 - Metabolism and nutrition disorders 10029885 Obesity, unspecified LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003035-28 Sponsor Protocol Number: APHP200132 Start Date*: 2022-02-22
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: " Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence " CAPTiRALL
    Medical condition: Relapsed or refractory B-ALL (any relapse after HSCT, 2nd relapse or later, refractory ALL), aged 1-25 years old, previously treated by Tisagenlecleucel (Kymriah ®), Cohort 1 presenting early loss ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002565-22 Sponsor Protocol Number: LOKON002 Start Date*: 2017-12-21
    Sponsor Name:Lokon Pharma AB
    Full Title: Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
    Medical condition: Colorectal, ovarian, pancreatic, gallbladder and bile duct cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000394-96 Sponsor Protocol Number: NEOGAP-CRC-01 Start Date*: 2023-01-31
    Sponsor Name:NEOGAP Therapeutics AB
    Full Title: A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer
    Medical condition: Stage IV colorectal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006312-38 Sponsor Protocol Number: SAKK 41/08 Start Date*: 2009-08-05
    Sponsor Name:SAKK (Swiss Group for Clinical Cancer Research)
    Full Title: Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced, K-ras mutated rectal cancer. A randomized multicenter phase I/II trial.
    Medical condition: Advanced K-ras mutated rectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003188-24 Sponsor Protocol Number: CA184-587 Start Date*: 2020-11-13
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001072-11 Sponsor Protocol Number: CO41012 Start Date*: 2019-08-21
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IB/III STUDY OF IPATASERTIB PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE LOCALLY ADVANCED UNRESECTABLE OR ...
    Medical condition: Hormone receptor (HR)-positive/HER2-negative locally advanced unresectable or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    20.0 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003348-31 Sponsor Protocol Number: 2007/311 Start Date*: 2008-05-15
    Sponsor Name:Department of Woman and Child health, Karolinska University Hospital
    Full Title: Progesterone at imminent premature birth Progesteron vid hotande förtidsbörd
    Medical condition: In this randomised, placebo-controlled pilot study the treatment group (n=30) will recieve a daily application of vaginal gel containing progesterone 90 mg/dose (Crinone, Seronomerck) until rupture...
    Disease:
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Under 18, Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004491-22 Sponsor Protocol Number: LIFE-PC-01 Start Date*: 2017-09-01
    Sponsor Name:Dept. Clinical Medicine, Aarhus Universit
    Full Title: Early detection of effects of chemotherapy in pancreatic cancer patients – a study using MR-hyperpolarization scanning based on hyperpolarized Pyruvate (13C) injection
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002314-17 Sponsor Protocol Number: JR-441-101 Start Date*: 2023-07-03
    Sponsor Name:JCR Pharmaceuticals Co., Ltd.
    Full Title: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA
    Medical condition: Mucopolysaccharidosis type IIIA (MPS IIIA) MPS III is an autosomal recessive disease characterized by the accumulation of HS in the tissues throughout the body due to a deficiency in enzymes involv...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003048-28 Sponsor Protocol Number: BO44426 Start Date*: 2023-03-01
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, ACTIVITY, AND PHARMACOKINETICS OF DIVARASIB IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH PREVIOUSLY UNTREATED...
    Medical condition: Untreated Advanced or Metastatic Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001635-91 Sponsor Protocol Number: ODX-MM-001 Start Date*: 2022-08-10
    Sponsor Name:DexTech Medical AB
    Full Title: A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001772-10 Sponsor Protocol Number: 2016-06 Start Date*: 2020-02-14
    Sponsor Name:Assistance Publique-Hôpitaux de Marseille
    Full Title: Phase I study of oral metronomic NAVELBINE® and HEMANGIOL®combination for children and teenagers with refractory/relapsing solid tumors
    Medical condition: Pediatric Solid tumor
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 71  72  73  74  75  76  77  78  79  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 29 08:00:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA